Plexision105 Jan, 2021Health
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision�s CLIA-certified, central laboratory in Pittsburgh.
Nova Tile And Stone Home Design Center - Reno
Tako Garage Door
Rollator Wheelchair
Aptive Pest Control
Masterofpuppies
F168
Twin68 Play
Wbb Gig
Roshini Childrens Hospital
Cooper Mclain